Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -20.99% is 108% below its 5-year average of -10.07%, near the low end of its 5-year range (-34.18%–22.10%).
48.93% below its 12-month average of -14.09%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 7.33%.
EBITDA MARGIN
-20.99%
EBITDA MARGIN AVG TTM
-14.09%
EBITDA MARGIN AVG 3Y
-12.44%
EBITDA MARGIN AVG 5Y
-10.07%
EBITDA MARGIN AVG 10Y
-7.36%
EBITDA MARGIN AVG 15Y
-18.50%
EBITDA MARGIN AVG 20Y
-28.30%
CURRENT VS TTM AVG
-48.93%
CURRENT VS 3Y AVG
-68.77%
CURRENT VS 5Y AVG
-108.47%
CURRENT VS 10Y AVG
-185.00%
CURRENT VS 15Y AVG
-13.49%
CURRENT VS 20Y AVG
+25.83%
OPKO Health, Inc.
Market Cap
$1.09B
EBITDA Margin
-20.99%
TTM Avg
-14.09%
3Y Avg
-12.44%
5Y Avg
-10.07%
Market Cap
$1.09B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.08B
EBITDA Margin
34.04%
TTM Avg
32.58%
3Y Avg
31.87%
5Y Avg
26.02%
Market Cap
$1.10B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
EBITDA Margin
-15.54%
TTM Avg
-15.54%
3Y Avg
-2.35%
5Y Avg
5.20%
Market Cap
$1.11B
EBITDA Margin
-5.96%
TTM Avg
-8.24%
3Y Avg
-13.85%
5Y Avg
-8.28%
Market Cap
$1.13B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OPKO Health, Inc. (OPK) | $1.09B | -20.99% | -14.09% | -12.44% | -10.07% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 34.04% | 32.58% | 31.87% | 26.02% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | N/A | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | -15.54% | -15.54% | -2.35% | 5.20% |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | -5.96% | -8.24% | -13.85% | -8.28% |
| Replimune Group, Inc. (REPL)vs › | $1.11B | N/A | N/A | N/A | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 3.96% | -13.21% | -146.19% | -104.68% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 21.12% | 16.04% | 11.58% | 9.26% |
Gross Margin
21.1%
EBITDA Margin
-21.0%
Operating Margin
-36.1%
Net Margin
-12.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 7.33% |
| 2026-03-31 | -23.20% |
| 2025-12-31 | -10.74% |
| 2025-09-30 | -20.29% |
| 2025-06-30 | -23.57% |
| 2025-03-31 | -29.13% |
| 2024-12-31 | -4.96% |
| 2024-09-30 | 22.10% |
| 2024-06-30 | -20.59% |
| 2024-03-31 | -26.28% |
| 2023-12-31 | -23.67% |
| 2023-09-30 | -21.32% |
| 2023-06-30 | 12.65% |
| 2023-03-31 | -1.75% |
| 2022-12-31 | -15.54% |
| 2022-09-30 | -34.18% |
| 2022-06-30 | 5.57% |
| 2022-03-31 | -13.55% |
| 2021-12-31 | -10.94% |
| 2021-09-30 | 14.72% |
| 2021-06-30 | 5.91% |
| 2021-03-31 | 10.72% |
| 2020-12-31 | 14.02% |
| 2020-09-30 | 10.03% |
| 2020-06-30 | 16.42% |
| 2020-03-31 | -8.85% |
| 2019-12-31 | -40.09% |
| 2019-09-30 | -6.65% |
| 2019-06-30 | -10.43% |
| 2019-03-31 | -23.15% |
| 2018-12-31 | -29.79% |
| 2018-09-30 | -3.82% |
| 2018-06-30 | 7.45% |
| 2018-03-31 | -7.00% |
| 2017-12-31 | -63.40% |
| 2017-09-30 | -12.48% |
| 2017-06-30 | -0.09% |
| 2017-03-31 | -5.40% |
| 2016-12-31 | -9.60% |
| 2016-09-30 | 0.74% |
| 2016-06-30 | 14.80% |
| 2016-03-31 | -1.83% |
| 2015-12-31 | 5.17% |
| 2015-09-30 | 2.91% |
| 2015-06-30 | -50.08% |
| 2015-03-31 | -177.47% |
| 2014-12-31 | -112.92% |
| 2014-09-30 | -225.17% |
| 2014-06-30 | -131.06% |
| 2014-03-31 | -119.93% |
| 2013-12-31 | -151.26% |
| 2013-09-30 | -73.84% |
| 2013-06-30 | -61.00% |
| 2013-03-31 | -10.66% |
| 2012-12-31 | -43.04% |
| 2012-09-30 | -56.84% |
| 2012-06-30 | -67.45% |
| 2012-03-31 | -74.27% |
| 2011-12-31 | -129.50% |
| 2011-09-30 | -69.99% |
| 2011-06-30 | -45.40% |
| 2011-03-31 | -48.01% |
| 2010-12-31 | -0.47% |
| 2010-09-30 | -61.74% |
| 2010-06-30 | -60.82% |
| 2010-03-31 | -39.07% |
| 2009-12-31 | -105.47% |
| 2009-09-30 | -358.96% |
| 2009-06-30 | -203.58% |
| 2009-03-31 | -352.72% |
| 2008-12-31 | -523.06% |
| 2008-09-30 | -185.70% |
| 2008-06-30 | -1162.12% |
| 2008-03-31 | -360.48% |
| 2007-12-31 | -1053.60% |
| 2007-03-31 | -3.33% |
| 2005-03-31 | -2200.00% |
| 2003-03-31 | -7892.31% |
| 2002-12-31 | -33750.00% |
